非小细胞肺癌中MET外显子14跳跃导致克唑替尼耐药的获得性机制 - Suppr

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

作者信息

Jin Wei, Shan Benjie, Liu Hu, Zhou Shoubing, Li Wenjuan, Pan Jing, Lin Lin, Hu Dandan, Pan Yueyin

机构信息

Department of Tumor Biotherapy (Ward 5 of the Department of Oncology), West district of The First Affiliated Hospital of USTC, Division of life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, Anhui Province, People's Republic of China.

Department of Oncology, The First Affiliated Hospital of USTC, Division of life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui Province, People's Republic of China.

出版信息

J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.

DOI:10.1016/j.jtho.2019.04.021

PMID:31055074

Abstract

摘要

相似文献

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中MET外显子14跳跃导致克唑替尼耐药的获得性机制

J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.在具有MET外显子14跳跃突变的非小细胞肺癌中，卡博替尼克服克唑替尼对获得性耐药突变MET D1228N的耐药性。

JCO Precis Oncol. 2021 Nov;5:849-853. doi: 10.1200/PO.21.00076.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.MET 外显子 14 跳跃型非小细胞肺癌中克唑替尼耐药的预先存在 MET Y1230C 突变的出现

J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中 MET 外显子 14 跳跃导致对克唑替尼获得性耐药。

J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.卡博替尼在 MET 外显子 14 阳性 NSCLC 伴脑转移患者中的颅内活性。

J Thorac Oncol. 2017 Jan;12(1):152-156. doi: 10.1016/j.jtho.2016.09.127. Epub 2016 Sep 28.

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.高水平 MET 扩增的非小细胞肺癌即使 MET 外显子 14 无改变，对克唑替尼也有应答。

J Thorac Oncol. 2017 Jan;12(1):141-144. doi: 10.1016/j.jtho.2016.09.116. Epub 2016 Sep 21.

Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.病例报告：MET 外显子 14 跳跃的 NSCLC 中曲妥珠单抗耐药的机制为 HER2 扩增。

Cancer Biol Ther. 2019;20(6):837-842. doi: 10.1080/15384047.2019.1566049. Epub 2019 Feb 11.

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.基于 DNA 的高度精确检测和治疗肺癌中 MET 外显子 14 跳跃突变的结果。

Lung Cancer. 2020 Feb;140:46-54. doi: 10.1016/j.lungcan.2019.11.010. Epub 2019 Nov 18.

Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.新型MET外显子14跳跃型初治肺腺癌对克唑替尼呈现原发性耐药。

J Thorac Oncol. 2018 Jul;13(7):e124-e126. doi: 10.1016/j.jtho.2018.02.030.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.MET 外显子 14 跳跃突变阳性非小细胞肺癌对克唑替尼和卡博替尼治疗有反应的病例系列研究。

Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.

引用本文的文献

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.MET 改变的非小细胞肺癌诊断与治疗专家共识

Cancer Biol Med. 2025 Apr 8;22(3):237-65. doi: 10.20892/j.issn.2095-3941.2024.0503.

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.在遗传性乳头状肾细胞癌中鉴定出的具有激活型N叶突变的MET变体仍然需要配体刺激。

Mol Oncol. 2025 Feb 20. doi: 10.1002/1878-0261.13806.

Intracranial response to capmatinib after progression on crizotinib in a patient with exon 14 skipping non-small cell lung cancer-a case report.一例14号外显子跳跃型非小细胞肺癌患者在克唑替尼治疗进展后对卡马替尼的颅内反应——病例报告

Transl Lung Cancer Res. 2024 Jul 30;13(7):1749-1755. doi: 10.21037/tlcr-23-769. Epub 2024 Jul 15.

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略

Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.

Recording and classifying MET receptor mutations in cancers.记录和分类癌症中的MET受体突变。

Elife. 2024 Apr 23;13:e92762. doi: 10.7554/eLife.92762.

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of  Non-small Cell Lung Cancer with MET Alterations].[MET改变的非小细胞肺癌靶向治疗的耐药机制与治疗策略]

Zhongguo Fei Ai Za Zhi. 2023 Sep 20;26(9):684-691. doi: 10.3779/j.issn.1009-3419.2023.102.33.

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.SYK 介导的上皮细胞状态与 MET 过表达肺癌中对 c-Met 抑制剂的反应相关。

Signal Transduct Target Ther. 2023 May 15;8(1):185. doi: 10.1038/s41392-023-01403-w.

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.福雷替尼可克服 MET 外显子 14 跳跃突变的 NSCLC 患者接受卡马替尼/替泊替尼治疗后的常见靶标耐药突变。

J Hematol Oncol. 2022 Jun 11;15(1):79. doi: 10.1186/s13045-022-01299-z.

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.KRAS 和 MET 基因在非小细胞肺癌中的作用：“驱动基因”家族的新成员。

Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211066064. doi: 10.1177/17534666211066064.

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.探讨针对肺癌的靶向治疗耐药的靶标机制时 Ba/F3 细胞系统的效用。

Cancer Sci. 2022 Mar;113(3):815-827. doi: 10.1111/cas.15263. Epub 2022 Jan 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献